The Australian Research Data Commons (ARDC) invites you to participate in a short survey about your
interaction with the ARDC and use of our national research infrastructure and services. The survey will take
approximately 5 minutes and is anonymous. It’s open to anyone who uses our digital research infrastructure
services including Reasearch Link Australia.
We will use the information you provide to improve the national research infrastructure and services we
deliver and to report on user satisfaction to the Australian Government’s National Collaborative Research
Infrastructure Strategy (NCRIS) program.
Please take a few minutes to provide your input. The survey closes COB Friday 29 May 2026.
Complete the 5 min survey now by clicking on the link below.
Metabolic disorders related to the modern lifestyle, including inactivity, obesity, the metabolic syndrome and type II diabetes, are responsible for a major proportion of the disease burden in Australia. Current treatment strategies are expensive and because they are directed at end-organ damage (heart failure, heart attacks etc), rather ineffective. This multispecialty, multidisciplinary group will undertake a series of unique studies aimed at understanding and preventing early cardiovascular c ....Metabolic disorders related to the modern lifestyle, including inactivity, obesity, the metabolic syndrome and type II diabetes, are responsible for a major proportion of the disease burden in Australia. Current treatment strategies are expensive and because they are directed at end-organ damage (heart failure, heart attacks etc), rather ineffective. This multispecialty, multidisciplinary group will undertake a series of unique studies aimed at understanding and preventing early cardiovascular complications of these metabolic conditions. Sensitive new cardiovascular imaging techniques will be used to detect preclinical abnormalities in the structure, function and metabolism of the heart and vasculature, facilitating the development of new strategies of exercise and lifestyle intervention to prevent these complications. While built on the successful current CCRE in Cardiovascular and Metabolic Disease, including multidisciplinary clinical research training, the new application involves major new directions in the interface between the liver and metabolic syndrome, and strategies for community-based prevention programs. The nursing intervention model, which will focus on workforce models of care, is especially important. The results of this study will provide information to address the need for different nursing models sought by the recent Productivity Commission Report.Read moreRead less
Identification Of Key Enzymes Required For Efficient Post-translational Modification And Multimerisation Of Adiponectin
Funder
National Health and Medical Research Council
Funding Amount
$92,364.00
Summary
Obesity is a major national and global health issue, with 62% of adult Australians being overweight/obese, associated with a number of diseases such as type 2 diabetes and cardiovascular disease. Fat tissue secretes hormones and dysregulation of these hormones contributes to the development of obesity-associated disease. This project aims to define processes governing the secretion of one key hormone and ultimately to identify targets for the treatment of obesity-associated complications.
I am a public health researcher in cardiovascular science and epidemiology evaluating programs for lowering the risk of chronic illness in Aboriginal and Torres Strait Islander populations.
Randomised Double-blind Placebo-controlled Trial Of Aspirin In Primary Prevention Of CVD Events Or Dementia In The Aged.
Funder
National Health and Medical Research Council
Funding Amount
$3,532,500.00
Summary
The single most important risk factor for cardiovascular disease is age. All men aged 75 years have a 10-15% risk of having a stroke or heart attack in the next 5 years. Low dose aspirin has been shown to prevent further strokes and heart attacks in people who have already had one. It has been also shown to protect people who have not had a heart attack or stroke but who are at increased risk. Given that the elderly are at increased risk why do we need to do a trial in this particular group? The ....The single most important risk factor for cardiovascular disease is age. All men aged 75 years have a 10-15% risk of having a stroke or heart attack in the next 5 years. Low dose aspirin has been shown to prevent further strokes and heart attacks in people who have already had one. It has been also shown to protect people who have not had a heart attack or stroke but who are at increased risk. Given that the elderly are at increased risk why do we need to do a trial in this particular group? The reason is that relatively few elderly patients were included in the previous prevention trials. Also while the elderly may have the most to gain from treatment, they also have the most to lose because they are more likely to suffer from side-effects. Aspirin prevents heart attacks by stopping clots forming in blood vessels. This also means that people taking it have an increased tendency to bleed. Thus though it may prevent strokes due to clots it may also increase the risk of strokes caused by bleeding. Bleeding from the gut is another major problem as aspirin tends to erode the lining of the stomach. Minor bleeding from the gut can also lower blood oxygen carrying capacity which may exacerbate other diseases associated with ageing, e.g. heart failure. Dementia may be caused by repeated clots in small or large vessels. Dementia is a particular problem in the elderly affecting 10% of 85 year olds. It is a major cause of loss of quality of life and a significant cost to the community. Aspirin may reduce the progression of such a disease leading to a maintained quality of life (QOL) for individuals and their families. As our age increases our years of life remaining decreases. This is self-evident. Thus the potential to add years to life reduces and the potential of diseases to adversely affect quality of life becomes more important. Thus it may be more important to prevent a nonfatal stroke that leads to institutionalisation than a fatal stroke. Hence QOL will be assessed.Read moreRead less
Clinical Approaches To Preventing Cardiovascular Disease
Funder
National Health and Medical Research Council
Funding Amount
$463,652.00
Summary
Cardiovascular disease (CVD) is the leading cause of death and disease burden globally. While many new treatments have been discovered in the last few decades to prevent CVD, surveys show many people do not receive these treatments. Dr. Chow is committed to using her skills as a cardiologist and a researcher to bridge this gap. Her program aims to identify novel, simple and scalable approaches to decrease the gap in preventative care and reduce the burden of CVD in Australia and beyond.
Improving Prevention Of Cardiovascualr Disease In High Risk Populations
Funder
National Health and Medical Research Council
Funding Amount
$408,388.00
Summary
Heart attack and stroke are the leading causes of death and disease burden globally. While there are highly effective treatments to prevent cardiovascular disease, surveys in Australia and other parts of the world indicate they are not being taken up. This program of research aims to improve prevention in individuals at high risk of heart attack and stroke by developing and testing strategies to increase the use of effective evidence-based treatment therapies.
I am a cardiologist and epidemiologist whose research focus is on large-scale clinical trials and epidemiological research into the prevention of cardiovascular disease, particularly in relation to treatment strategies for acute coronary syndromes, dyslip